6-K - Scinai Immunotherapeutics Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Scinai Immunotherapeutics Ltd. executed a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., extending the option conditions deadline to August 31, 2026, and option exercise period to September 30, 2026, and submitted a revised €12 million non-dilutive FENG SMART Path application for an integrated €15 million R&D program for PC111. The funding, if awarded, would support advancement through human proof of concept while preserving balance sheet flexibility.

Key Takeaways

1Executed Second Amendment to Binding Option Agreement with PinCell S.r.l.

2Option conditions fulfillment deadline extended to August 31, 2026

3Option exercise period extended to September 30, 2026

4Submitted revised FENG SMART Path application for €12 million (80% of €15 million R&D program)

5Application supports PC111 development for pemphigus vulgaris and SJS/TEN through human proof of concept

6Funding decision expected within 3-4 months

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Transaction Details

Material Agreement

Agreement: Second Amendment to Binding Option Agreement
Parties: Scinai Immunotherapeutics Ltd., PinCell S.r.l.

•Deadline for fulfillment of the option conditions extends to August 31, 2026
•Option exercise period extends to September 30, 2026
•Aligns the option timeline with the grant evaluation process

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE DATED MARCH 2, 2026